<a href="https://www.fiercebiotech.com/biotech/asco-bms-celmod-drug-stands-out-doubling-pfs-ph-3-myeloma-study" hreflang="en">ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study</a>
Bristol Myers Squibb's CELMoD drug, mezigdomide, has shown promising results in a phase 3 trial, doubling progression-free survival for patients with relapsed or refractory multiple myeloma when used in combination with Kyprolis and dexamethasone. While the treatment demonstrated significant efficacy, it also resulted in a higher incidence of severe side effects compared to the control group.
Bristol Myers Squibb's CELMoD drug, mezigdomide, has shown promising results in a phase 3 trial by more than doubling progression-free survival in patients with relapsed or refractory multiple myeloma, suggesting it could become a new standard of care. This positions BMS as a leader in targeted protein degradation therapies, making it a potential area for investment or partnership as they advance discussions with the FDA and explore broader applications for CELMoD drugs in oncology.